Dog,

Please don't encourage discussion of Naked Shorting or even Shorting of CGNH. Such a discussion is IMO not appropriate for this board; Wow (Showmoney) can have that discussion on RB. Posters on this board need to focus on Cardiogenics meeting its publicly stated timelines on completion of the two studies necessary to complete development of the POC Analyzer.

As we have discussed, the pending dilution is likely to be a PIPE sufficient in size to provide funds to conduct the head-to-head study and cover G&A. IMO the amount is likely to be between $1-2 million at 10 cents per share. If the head-to-head study produces a statistically significant p-value, Dr G can do a third PIPE or licensing deal to conduct the larger clinical trial and fund the company through the FDA registration process.

Ante